Royalty Pharma (RPRX) Competitors $31.11 -0.68 (-2.14%) Closing price 04:00 PM EasternExtended Trading$30.39 -0.72 (-2.31%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RPRX vs. CORT, JAZZ, PRGO, SUPN, PCRX, OMER, NKTR, ASMB, CPIX, and LLYShould you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceuticals" industry. Royalty Pharma vs. Corcept Therapeutics Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Omeros Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Royalty Pharma (NASDAQ:RPRX) and Corcept Therapeutics (NASDAQ:CORT) are both finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, community ranking, risk, analyst recommendations, valuation, earnings and institutional ownership. Does the media favor RPRX or CORT? In the previous week, Corcept Therapeutics had 43 more articles in the media than Royalty Pharma. MarketBeat recorded 60 mentions for Corcept Therapeutics and 17 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.25 beat Corcept Therapeutics' score of 0.51 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 13 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 24 Very Positive mention(s) 5 Positive mention(s) 16 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Is RPRX or CORT more profitable? Royalty Pharma has a net margin of 37.94% compared to Corcept Therapeutics' net margin of 22.35%. Corcept Therapeutics' return on equity of 24.54% beat Royalty Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Royalty Pharma37.94% 24.40% 14.01% Corcept Therapeutics 22.35%24.54%20.24% Do analysts prefer RPRX or CORT? Royalty Pharma presently has a consensus target price of $41.60, suggesting a potential upside of 34.82%. Corcept Therapeutics has a consensus target price of $143.25, suggesting a potential upside of 89.15%. Given Corcept Therapeutics' higher probable upside, analysts plainly believe Corcept Therapeutics is more favorable than Royalty Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Royalty Pharma 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, RPRX or CORT? Royalty Pharma has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Do institutionals & insiders have more ownership in RPRX or CORT? 54.3% of Royalty Pharma shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by company insiders. Comparatively, 20.5% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer RPRX or CORT? Corcept Therapeutics received 221 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 71.37% of users gave Corcept Therapeutics an outperform vote while only 67.99% of users gave Royalty Pharma an outperform vote. CompanyUnderperformOutperformRoyalty PharmaOutperform Votes32567.99% Underperform Votes15332.01% Corcept TherapeuticsOutperform Votes54671.37% Underperform Votes21928.63% Which has preferable valuation and earnings, RPRX or CORT? Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoyalty Pharma$2.26B7.86$858.98M$1.4521.28Corcept Therapeutics$675.04M11.84$106.14M$1.2461.08 SummaryCorcept Therapeutics beats Royalty Pharma on 11 of the 18 factors compared between the two stocks. Remove Ads Get Royalty Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RPRX vs. The Competition Export to ExcelMetricRoyalty PharmaPharmaceutical IndustryFinance SectorNASDAQ ExchangeMarket Cap$17.76B$6.51B$10.53B$7.14BDividend Yield2.82%2.85%5.42%4.05%P/E Ratio21.256.7721.3517.35Price / Sales7.86188.6224.9684.30Price / Cash7.9465.6717.6234.64Price / Book1.725.632.583.78Net Income$858.98M$142.37M$1.03B$247.18M7 Day Performance-1.64%-11.25%-5.06%-7.74%1 Month Performance-7.40%-14.25%494.21%-10.35%1 Year Performance7.43%-18.14%530.63%-7.76% Royalty Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RPRXRoyalty Pharma4.6744 of 5 stars$31.11-2.1%$41.60+33.7%+10.4%$17.93B$2.26B21.4680Positive NewsHigh Trading VolumeCORTCorcept Therapeutics4.3127 of 5 stars$114.22+109.1%$127.00+11.2%+209.4%$12.05B$675.04M90.65300Analyst ForecastInsider TradeOptions VolumeAnalyst RevisionGap DownHigh Trading VolumeJAZZJazz Pharmaceuticals4.8567 of 5 stars$124.15+1.0%$187.71+51.2%+3.3%$7.54B$4.07B17.493,200Insider TradePositive NewsGap DownHigh Trading VolumePRGOPerrigo4.9213 of 5 stars$28.07+0.0%$33.00+17.6%-13.3%$3.83B$4.37B-23.998,900Short Interest ↓News CoveragePositive NewsGap DownSUPNSupernus Pharmaceuticals2.7786 of 5 stars$32.75+1.4%$36.00+9.9%-4.0%$1.83B$661.82M30.61580Analyst UpgradeShort Interest ↓PCRXPacira BioSciences3.2985 of 5 stars$24.85-0.2%$27.22+9.5%-16.3%$1.15B$700.97M-12.24720Gap DownOMEROmeros3.4347 of 5 stars$8.22-3.0%$22.50+173.7%+133.7%$476.35MN/A-3.56210Analyst ForecastAnalyst RevisionNews CoverageNKTRNektar Therapeutics4.2356 of 5 stars$0.68-7.9%$4.92+623.0%-42.3%$126.55M$98.43M-0.81220Analyst RevisionGap DownASMBAssembly Biosciences3.3849 of 5 stars$9.56-10.0%$33.00+245.2%-32.5%$71.73M$28.52M-1.42100Gap DownCPIXCumberland Pharmaceuticals1.0015 of 5 stars$4.23-4.1%N/A+150.0%$59.09M$37.87M-5.4980LLYEli Lilly and Company4.9037 of 5 stars$825.42+0.4%$1,009.72+22.3%+1.6%$782.64B$45.04B70.4939,000Gap Down Remove Ads Related Companies and Tools Related Companies Corcept Therapeutics Competitors Jazz Pharmaceuticals Competitors Perrigo Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Omeros Competitors Nektar Therapeutics Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RPRX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.